Johnson & Johnson (JNJ)vsPrestige Brand Holdings Inc (PBH)
JNJ
Johnson & Johnson
$232.77
-2.08%
HEALTHCARE · Cap: $536.54B
PBH
Prestige Brand Holdings Inc
$47.18
+3.83%
HEALTHCARE · Cap: $2.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 8751% more annual revenue ($96.36B vs $1.09B). JNJ leads profitability with a 21.8% profit margin vs 17.5%. PBH appears more attractively valued with a PEG of 1.45. PBH earns a higher WallStSmart Score of 65/100 (B-).
JNJ
Buy59
out of 100
Grade: C
PBH
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-71.4%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Margin of Safety
-54.8%
Fair Value
$42.62
Current Price
$47.18
$4.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 26.8%
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Weak financial health signals
Revenue declined 5.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : PBH
The strongest argument for PBH centers on Price/Book, P/E Ratio, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 26.8%. PEG of 1.45 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PBH
The primary concerns for PBH are Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PBH is a declining play — different risk/reward profiles.
PBH carries more volatility with a beta of 0.35 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
PBH scores higher overall (65/100 vs 59/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Prestige Brand Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company is headquartered in Tarrytown, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?